This study evaluates changes in skin quality and self-esteem among breast cancer patients who are initiating aromatase inhibitor therapy.
* Female ≥ 18 years
Postmenopausal women suitable to receive aromatase inhibitor as per physician's discretion
Histologically confirmed adenocarcinoma of the breast stage 0-III with estrogen receptor (ER) and/or progesterone receptor (PR) positive per American Society of Clinical Oncology (ASCO)/ College of American Pathologists (CAP) guideline and any human epidermal growth factor receptor 2 (HER2)
Patients must not have received any prior chemotherapy or endocrine therapy for their current breast cancer. Patients who received tamoxifen or raloxifene or another agent for prevention of breast cancer may be included
* Patients who have previously taken AIs
Patients using prescription tretinoin, neurotoxin injections, fillers, facial lasers, microneedling, or facials within 6 months of study consent
Women 18 years or older with diagnosis of estrogen receptor (ER) positive breast cancer.
Cohort
Prospective
Non-Interventional Study
Other interventionNon-interventional study
Changes in skin quality
Changes in skin quality measured as incidence and severity of skin quality changes using VISIA-CA technology (skin analysis imaging system) and facial skin assessment photography.
Click on the lead sponsor to view all of their trials.
